Stonepine Capital Management’s Interpace Biosciences, Inc. Common Stock IDXG Stock Holding History

Stonepine Capital Management’s Portfolio IDXG Stock Details IDXG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-284,730	Closed	-$880K	–	24
2020 Q3	$880K	Buy	+284,730	New	+$1.29M	0.92%	16
2020 Q2	–	Sell	-178,295	Closed	-$924K	–	28
2020 Q1	$924K	Buy	178,295 +83,910	+89%	+$608K	0.98%	24
2019 Q4	$472K	Sell	94,385 -21,653	-19%	-$140K	0.33%	21
2019 Q3	$922K	Sell	116,038 -59,280	-34%	-$463K	0.89%	19
2019 Q2	$1.27M	Buy	175,318 +31,915	+22%	+$234K	0.88%	21
2019 Q1	$1.15M	Buy	+143,403	New	+$1.35M	0.66%	26

Other funds holding IDXG

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Allworth Financial Folsom, California $23.6B AUM 20.99% 1-Year Est. Return

FDCDDQ

Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $32.7B AUM 35.71% 1-Year Est. Return

Stonepine Capital Management's IDXG Position: Q4 2020 in Review

Stonepine Capital Management sold out of Interpace Biosciences, Inc. Common Stock (IDXG) in Q4 2020, closing a stake of 284,730 shares — an estimated $880K sold.

Stonepine Capital Management first reported a position in IDXG in Q1 2019 and held it in 6 quarters. The position peaked at $1.27M in Q2 2019. 12 funds tracked by Wall St. Rank hold IDXG as of Q4 2020.

Stonepine Capital Management reported no remaining Interpace Biosciences, Inc. Common Stock position as of Q4 2020 after selling out during the quarter.
Stonepine Capital Management sold 284,730 Interpace Biosciences, Inc. Common Stock shares in Q4 2020, an estimated $880K.
Stonepine Capital Management first reported a position in Interpace Biosciences, Inc. Common Stock in Q1 2019 and held it in 6 quarters.
Stonepine Capital Management's Interpace Biosciences, Inc. Common Stock position peaked at $1.27M in Q2 2019.
12 funds tracked by Wall St. Rank held Interpace Biosciences, Inc. Common Stock as of Q4 2020.

Based on Stonepine Capital Management's 13F filing for Q4 2020, filed 12 Feb 2021.